S-1: TransCode Therapeutics Files for Resale of Common Stock and Warrants Following Private Placement

TransCode Therapeutics is registering the resale of common stock and warrants issued in a recent private placement, as the company continues to develop its oncology-focused platform.

Summary

• TransCode Therapeutics has filed an S-1 registration statement to allow selling stockholders to resell 173,033 shares of common stock, 470,007 shares underlying pre-funded warrants, up to 4,050,953 shares underlying Series C warrants, and up to 12,152,856 shares underlying Series D warrants.
• These securities were issued in a private placement (PIPE) completed on November 26, 2024.
• The Series C and D warrants have an initial exercise price of $15.675 per share, with potential adjustments based on future stock issuances and reset dates.
• The company will not receive proceeds from the resale of common stock but will receive proceeds from the cash exercise of warrants.
• TransCode is a clinical-stage company focused on oncology, with its lead candidate, TTX-MC138, currently in a Phase I/II clinical trial.
• The company is also working to maintain its Nasdaq listing, having received an extension until December 31, 2024, to regain compliance.
• A 1-for-33 reverse stock split was completed on December 4, 2024, to help regain compliance with Nasdaq listing rules.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has promising technology and preclinical results, it faces significant financial challenges, potential delisting from Nasdaq, and is heavily reliant on the success of a single drug candidate. The sentiment is cautiously optimistic but tempered by substantial risks.

Positives

• The company has a novel therapeutic agent, TTX-MC138, targeting miRNA-10b, a key driver of metastasis.
• Preclinical studies of TTX-MC138 have shown complete regressions of metastases in mouse models of breast and pancreatic cancer.
• The company has received an Investigational New Drug (IND) Study May Proceed letter from the FDA for its Phase I/II clinical trial.
• The company has completed the first cohort of patients in its Phase I clinical trial and received authorization to proceed with the second cohort.
• The company received a $1,999,972 NIH SBIR award to support clinical trial activities.
• The company's proprietary TTX delivery platform is designed to overcome challenges in delivering RNA therapeutics to tumors and metastases.
• The company has a modular design engine to customize the development of targeted therapeutics.

Negatives

• The company is not in compliance with certain Nasdaq listing requirements and faces potential delisting.
• The company has a low cash position and requires additional financing to support operations.
• The company has narrowed its focus primarily to the continued execution of its Phase I/II clinical trial with TTX-MC138, with other pipeline development on hold.
• The company has reduced headcount from 19 to 8 employees as part of restructuring efforts.
• The company is heavily dependent on the success of TTX-MC138, which is still in early stages of development.
• The company relies on third parties for clinical trials and manufacturing.
• The company has identified material weaknesses in its internal control over financial reporting.

Risks

• The company's low cash position and need for additional financing pose a significant risk.
• There is a risk of delisting from the Nasdaq Capital Market due to non-compliance with listing rules.
• The company's business is highly dependent on the success of TTX-MC138, which is in early stages of development.
• The company relies on third parties for clinical trials and manufacturing, which could lead to delays or disruptions.
• The company faces substantial competition in the pharmaceutical industry.
• The company's stock price may be volatile and fluctuate substantially.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company may need to seek an in-court or out-of-court restructuring of its liabilities.

Future Outlook

The company plans to complete the stage 1a portion of its Phase I/II clinical trial by the second quarter of 2026, subject to available capital. They are also in discussions with strategic partners and may advance development of preclinical assets if capital is available. The company may also file for European Orphan Drug Designation for TTX-MC138 in pancreatic cancer.

Management Comments

• TransCode was created on the belief that cancer can be defeated through the intelligent design and effective delivery of targeted therapeutics.
• The company believes that clinical development of TTX-MC138 has the potential for clinical benefit in patients with metastatic cancer.
• The company believes that its proprietary TTX delivery platform has the potential to resolve key challenges in delivering RNA therapeutics.
• The company believes that the ability to deliver targeted therapeutics inside tumors and metastases will potentially allow them to target genes and other important biomarkers for cancer treatment that have until now remained undruggable using other delivery systems.

Industry Context

The document highlights the significant unmet medical need in metastatic cancer treatment, with the global market expected to reach $136.9 billion by 2032. TransCode's focus on targeted RNA therapeutics and its proprietary delivery platform positions it to potentially address this market. The company's approach contrasts with traditional cancer therapies that primarily target primary tumors, while TransCode is focused on metastatic disease.

Comparison to Industry Standards

• The document mentions that many competitive delivery approaches rely on lipid particles or chemical structures, such as GalNAc, which effectively target sites in the liver but not sites in tumors and metastases elsewhere. TransCode's TTX platform is designed to overcome these limitations.
• The company's approach to targeting microRNA-10b is unique, as most anti-cancer therapies target primary tumors and not metastatic disease specifically. The company's preclinical results in mouse models of breast and pancreatic cancer are promising, showing complete regressions of metastases.
• The company's use of iron-oxide nanoparticles, which have an excellent clinical safety record, is a differentiator from other delivery approaches.
• The company's modular design approach allows for customization of therapeutics, which is a competitive advantage in the rapidly evolving field of RNA therapeutics.

Stakeholder Impact

• Shareholders face the risk of dilution from the resale of shares and the exercise of warrants.
• Shareholders face the risk of loss of investment if the company is delisted from Nasdaq or if the company needs to restructure its liabilities.
• Employees have been impacted by headcount reductions as part of restructuring efforts.
• Customers (potential patients) may benefit from the development of new cancer treatments.
• Suppliers and creditors face the risk of non-payment if the company's financial situation worsens.

Next Steps

• The company will continue its Phase I/II clinical trial with TTX-MC138.
• The company will work to regain compliance with Nasdaq listing rules by December 31, 2024.
• The company will hold a shareholder meeting to obtain Stockholder Approval for the warrants.
• The company may seek strategic partnerships for its therapeutic candidates.
• The company may advance development of preclinical assets if capital is available.
• The company may file for European Orphan Drug Designation for TTX-MC138 in pancreatic cancer.

Key Dates

Keywords

oncology, metastatic cancer, RNA therapeutics, microRNA-10b, TTX-MC138, clinical trial, Nasdaq, reverse stock split, private placement, warrants, drug delivery, biotechnology